Increased Oxidative Damage and Reduced DNA Repair Enzyme XPD Involvement in High Glucose-Mediated Enhancement of Levobupivacaine-Induced Neurotoxicity
- 369 Downloads
Levobupivacaine is one of the major clinical local anesthetics, but it can cause neuron toxic damage. Hyperglycemia can cause neuronal DNA oxidative damage and inhibit expression of the DNA repair gene Xeroderma pigmentosum complementation group D (XPD). This study was designed to determine whether high glucose levels inhibit XPD expression and enhance levobupivacaine-induced DNA damage. We evaluated XPD mRNA and protein expression in SH-SY5Y cells after glucose and levobupivacaine exposure. We next investigated cells reactive oxygen species (ROS) levels, DNA damage and apoptosis with redox-sensitive fluorescent dye DCFH-DA (2′,7′-dichlorofluorescein diacetate), comet assays, flow cytometry, and TUNEL (terminal deoxynucleotidyl transferased UTP nick end labeling) assays. XPD expression was inhibited in cells exposed to prolonged high glucose with a concomitant increase in ROS production and more severe DNA damage compared to control culture conditions, and these changes were further exacerbated by levobupivacaine. Our findings indicate that subjects with diabetes may experience more detrimental effects following local anesthetic use.
KeywordsXPD High glucose Neurotoxicity Levobupivacaine SH-SY5Y cells
Xeroderma pigmentosum complementation group D
Nucleotide excision repair
Olive tail moment
This study was supported by the National Science Foundation of China (Grant No. 81271390) and Natural Science Foundation for the Youth (Grant No. 81400995). None of the authors have financial relationships with biotechnology manufacturers, pharmaceutical companies, or other commercial entities with an interest in the subject matter or materials discussed in the manuscripts.
- 1.Hebl JR, Kopp SL, Schroeder DR, Horlocker TT (2006) Neurologic complications after neuraxial anesthesia or analgesia in patients with preexisting peripheral sensorimotor neuropathy or diabetic polyneuropathy. Anesth Analg 103:1294–1299. doi: 10.1213/01.ane.0000243384.75713.df CrossRefPubMedGoogle Scholar
- 7.Borazan M, Karalezli A, Oto S, Akova YA, Karabay G, Kocbiyik A, Celasun B, Demirhan B (2009) Induction of apoptosis of rabbit corneal endothelial cells by preservative-free lidocaine hydrochloride 2%, ropivacaine 1%, or levobupivacaine 0.75%. J Cataract Refract Surg 35:753–758. doi: 10.1016/j.jcrs.2008.12.016 CrossRefPubMedGoogle Scholar
- 8.Takenami T, Wang G, Nara Y, Fukushima S, Yagishita S, Hiruma H, Kawakami T, Okamoto H (2012) Intrathecally administered ropivacaine is less neurotoxic than procaine, bupivacaine, and levobupivacaine in a rat spinal model. Can J Anaesth 59:456–465. doi: 10.1007/s12630-012-9685-9 CrossRefPubMedGoogle Scholar
- 11.Spencer DM, Bilardi RA, Koch TH, Post GC, Nafie JW, Kimura K, Cutts SM, Phillips DR (2008) DNA repair in response to anthracycline-DNA adducts: a role for both homologous recombination and nucleotide excision repair. Mutat Res 638:110–121. doi: 10.1016/j.mrfmmm.2007.09.005 CrossRefPubMedGoogle Scholar
- 20.Broughton BC, Thompson AF, Harcourt SA, Vermeulen W, Hoeijmakers JH, Botta E, Stefanini M, King MD, Weber CA, Cole J, Et A (1995) Molecular and cellular analysis of the DNA repair defect in a patient in xeroderma pigmentosum complementation group D who has the clinical features of xerodermapigmentosum and Cockayne syndrome. Am J Hum Genet 56:167–174PubMedCentralPubMedGoogle Scholar
- 31.Abdulrahman W, Iltis I, Radu L, Braun C, Maglott-Roth A, Giraudon C, Egly JM, Poterszman A (2013) ARCH domain of XPD, an anchoring platform for CAK that conditions TFIIH DNA repair and transcription activities. Proc Natl Acad Sci USA 110:E633–E642. doi: 10.1073/pnas.1213981110 PubMedCentralCrossRefPubMedGoogle Scholar